Information Provided By: 
Fly News Breaks for April 10, 2017
TXMD
Apr 10, 2017 | 10:12 EDT
Stifel analyst Annabel Samimy expects the deficiencies brought up in the FDA letter to TherapeuticsMD are not clinical. She reminds investors that all doses on TX-001HR hit all objective and subjective co-primary endpoints. It remains unclear whether the FDA action date of May 7 will be maintained, the analyst adds. Samimy has a Buy rating on TherapeuticsMD with a $20 price target. The stock in early trading is down 19% to $6.25.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
